Pursuing Productive Pharma Partnerships In Korea
Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others’ strengths, delegates at a recent conference in Seoul heard.
You may also be interested in...
In an ongoing series of joint R&D programs with big foreign pharma firms, the Korea Drug Development Fund has tied up with MSD to support the development of novel cancer therapies.
Dong-A ST’s in-house developed DPP-4 inhibitor evogliptin is set to enter major markets, including the US and Europe, through a new licensing deal with Tobira that will focus on the treatment of non-alcoholic steatohepatitis (NASH) rather than diabetes.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.